

## DAFTAR PUSTAKA

- Abbas, A. K., Lichtman, A. H., & Pillai, S. (2018). *Cellular and Molecular Immunology*. 9th ed. Philadelphia: Elsevier.
- Azzawi, M., Kan, S. W., Hillier, V., Yonan, N., Hutchinson, I. V., & Hasleton, P. S. (2005). 'The distribution of cardiac macrophages in myocardial ischaemia and cardiomyopathy', *Histopathology*, *46*, p314-319.
- Billiet, L., Doaty, S., Katz, J. D., & Velasquez, M. T. (2014). 'Review of hyperuricemia as new marker for metabolic syndrome', *ISRN Rheumatology*, *2014*, p1-7.
- Cronstein, B. N., & Terkeltaub, R. (2006). 'The inflammatory process of gout and its treatment', *Arthritis research & therapy*, *8*, p1-41.
- Derbre, F., Ferrando, B., Gomez-Cabrera, M., Sanchis-Gomar, F., Martinez-Bello, V., & Olaso-Gonzales, G. (2012). 'Inhibition of xanthine oxidase by allopurinol prevents skeletal muscle atrophy: role of p38 MAPKinase and E3 ubiquitin ligases', *PLoS ONE*, *7*(10).
- Din, U. A., Salem, M. M., & Abdulazim, D. O. (2017). 'Uric acid in the pathogenesis of metabolic, renal, and cardiovascular diseases: a review', *Journal of Advanced Research*, *8*(5), p537-548.
- Doehner, W., & Anker, S. D. (2005). 'Uric acid in chronic heart failure', *Seminars in Nephrology*, *24*, p61-66.
- Eroschenko, V. P. (2013). *diFiore's Atlas of Histology With Functional Correlation*. 12th ed. Philadelphia: Wolter Kluwers | Lippincott Williams & Wilkins.
- Frantz, S., & Nahrendorf, M. (2014). 'Cardiac macrophages and their role in ischaemic heart disease', *Cardiovasclar Research*, *102*(2), p240-248.
- Goodman, L. S., Gilman, A., Brunton, L. L., Chabner, B. A., & Knollmann, B. C. (2011). *Goodman & Gilman's The Pharmacological Basis of Therapeutics*. 12th ed. New York: McGraw-Hill Medical.
- Haryono, A., Nugraningsih, D. A., Sari, D. C., Romi, M. M., & Arfian, N. (2018). 'Reduction of serum uric acid associated with attenuation of renal injury, inflammation and macrophages M1/M2 ratio in hyperuricemic mice model', *Kobe Journal of Medical Science*, *64*(3), pE107-E114.
- Hill, M. A. (2019). *Embryology Cardiac Muscle Histology* [Online]. Available at: [https://embryology.med.unsw.edu.au/embryology/index.php/Cardiac\\_Muscle\\_Histology/](https://embryology.med.unsw.edu.au/embryology/index.php/Cardiac_Muscle_Histology/) (Accessed: 29 October 2019)
- Kanellis, J., Watanabe, S., Li, J. H., Kang, D. H., Li, P., Nakagawa, T., *et al.* (2003). 'Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2', *Hypertension*, *41*, p1287-1293.
- Kang, L.-L., Zhang, D.-M., Ma, C.-H. Z.-H., Jia, K.-K. L.-H., Wang, R., & Kong, L.-D. (2016). 'Cinnamaldehyde and allopurinol reduce fructose-induced cardiac inflammation and fibrosis by attenuating CD36-mediated TLR4/6-IRAK4/1 signaling to suppress NLRP3 inflammasome activation', *Scientific Reports*, *8*(6), p1-18.

- Karim, B., Nasution, S. A., Wijaya, I. P., & Harimurti, K. (2015). 'Hyperuricemia as a risk factors of major adverse cardiac events in patients with acute coronary syndrome: a retrospective cohort study', *Acta Medica Indonesiana - The Indonesian Journal of Internal Medicine*, 47(4), p320-325.
- Kelkar, A., Kuo, A., & Frishman, W. H. (2011). 'Allopurinol as a Cardiovascular Drug', *Cardiology in Review*, 19(6), p265-271.
- Kindermann, I., Barth, C., Mahfoud, F., Ukena, C., Lenski, M., Yilmaz, A., *et al.* (2012). 'Update on myocarditis', *Journal of the American College of Cardiology*, 59(9), p779-92.
- Krishnan, E. (2014). 'Interaction of inflammation, hyperuricemia, and the prevalence of hypertension among adults free of metabolic syndrome: NHANES 2009-2010', *Journal of American Heart Association*, p1-10.
- Kumar, V., Abbas, A. K., & Aster, J. C. (2013). *Robbins Basic Pathology*. 9th ed. Philadelphia : Elsevier Saunders.
- Kushiyaama, A., Nakatsu, Y., Matsunaga, Y., Yamamotoya, T., Mori, K., Ueda, K., *et al.* (2016). 'Role of uric acid metabolism-related inflammation in the pathogenesis of metabolic syndrome components such as atherosclerosis and nonalcoholic steatohepatitis', *Mediators of Inflammation*, 2016, p1-15.
- Kuwabara, M. (2015). 'Hyperuricemia, cardiovascular disease, and hypertension', *Pulse*, 3, p242-252.
- Larsen, K. S., Pottegard, N., Lindegaard, H. M., & Hallas, J. (2016). 'Effect of allopurinol on cardiovascular outcomes in hyperuricemic patients: a cohort study', *The American Journal of Medicine*, 129(3), p299-306.
- Li, H., & Sun, B. (2007). 'Toll-like receptor 4 in atherosclerosis', *Journal of cellular and molecular medicine*, 11(1), p88-95.
- Lilly, L. S. (2016). *Pathophysiology of Heart Disease*. 6th ed. Philadelphia: Wolters Kluwer.
- Liu-Bryan, R., Scott, P., Sydlaske, A., Rose, D. M., & Terkeltaub, R. (2005). 'Innate immunity conferred by toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal-induced inflammation', *Arthritis & Rheumatism*, 52(9), p2936-2946.
- Ma, Y., Mouton, A. J., & Lindsey, M. L. (2017). 'Cardiac macrophage biology in the steady-state heart, the aging heart, and following myocardial infarction', *Translational Research: The Journal of Laboratory and Clinical Medicine*, 191, p15-28.
- Maiuolo, J., Oppedisano, F., Gratteri, S., Muscoli, C., & Mollace, V. (2016). 'Regulation of uric acid metabolism and excretion', *International Journal of Cardiology*, p8-14.
- Melgarejo, E., Medina, M. A., Sanchez-Jimenez, F., & Urdiales, J. L. (2009). 'Monocyte chemoattractant protein-1: a key mediator in inflammatory processes', *The International Journal of Biochemistry & Cell Biology*(41), p998-1001.
- Mescher, A. L. (2016). *Junqueira's Basic Histology Text and Atlas*. 14th ed. New York: McGraw Hill Education.

- Molteni, M., Gemma, S., & Rossetti, C. (2016). 'The role of toll-like receptor 4 in infectious and noninfectious disease', *Mediators of Inflammation*, 2016, p1-9.
- Moore, K. L., Dalley, A. F., & Agur, A. M. (2014). *Clinically Oriented Anatomy*. 7th ed. Philadelphia: Lippincott Williams & Wilkins.
- Morimoto, H., & Takahashi, M. (2007). 'Role of monocyte chemoattractant protein-1 in myocardial infarction', *International Journal of Biomedical Science*, 3(3), p159-167.
- Muiesan, M. L., Agabiti-Rosei, C., Painsi, A., & Salvetti, M. (2016). 'Uric acid and cardiovascular disease: an update', *European Cardiology Review*, 11(1), p54-59.
- Murphy, K., & Weaver, C. (2017). *Janeway's Immunology*. 9th ed. New York: Garland Science.
- Nakagomi, A., Saiki, Y., Noma, S., Kohashi, K., Morisawa, T., Kosugi, M., *et al.* (2015). 'Effects of febuxostat and allopurinol on the inflammation and cardiac function in chronic heart failure patients with hyperuricemia', *IJC Metabolic & Endocrine*, 8, p46-55.
- Niu, J., & Kolattukudy, P. E. (2009). 'Role of MCP-1 in cardiovascular disease: molecular mechanisms and clinical implications', *Clinical Science*(117), p95-109.
- Overbergh, L., Giulietti, A., Valckx, D., Decallonne, B., Bouillon, R., & Mathieu, C. (2003). 'The use of real-time reverse transcriptase PCR for the quantification of cytokine gene expression', *Journal of Biomolecular Techniques*, 14(1), p33-43.
- Pal, P., Nivorozhkin, A., & Szabo, C. (2006). 'Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol', *Pharmacological Reviews*, 58(1), p87-114.
- Peglow, S., Roledo, A., Anaya-Prado, R., Lopez-Neblina, F., & Toledo-Pereya, L. (2011). 'Allopurinol and xanthine oxidase inhibition in liver ischemia reperfusion', *Journal of Hepato-biliary-pancreatic Sciences*, 18(2), p137-146.
- Ridi, R. E., & Tallima, H. (2017). 'Physiological functions and pathogenic potential of uric acid: a review', *Journal of Advanced Research*, p487-493.
- Romi, M. M., Arfian, N., Tranggono, U., Setyaningsih, W. A., & Sari, D. C. (2017). 'Uric acid causes kidney injury through inducing fibroblast expansion, Endothelin-1 expression, and inflammation', *BMC Nephrology*, 18(1), p326.
- Sagor, A. T., Tabassum, N., Poto, A., & Alam, A. (2015). 'Xanthine oxidase inhibitor, allopurinol, prevented oxidative stress, fibrosis, and myocardial damage in isoproterenol induced age rats', *Oxidative Medicine and Cellular Longevity*, 2015, p1-9.
- Sattui, S. E., & Gaffo, A. L. (2016). 'Treatment of hyperuricemia in gout: current therapeutic options, latest developments and clinical implications', *Therapeutic Advances in Musculoskeletal Disease*, 8(4), p145-159.

- Stoll, L. L., Denning, G. M., & L., W. N. (2004). 'Potential role of endotoxin as a proinflammatory mediator of atherosclerosis', *Arteriosclerosis, Thrombosis, and Vascular Biology*, 24(12), p2227-2236.
- Yang, Y., Lv, J., Jiang, S., Ms, Z., Wang, D., Hu, W., *et al.* (2016). 'The emerging role of toll-like receptor 4 in myocardial inflammation', *Cell Death and Disease*, 7, p1-10.
- Yu, L., & Feng, Z. (2017). 'The role of toll-like receptor signaling in the progression of heart failure', *Mediators of Inflammation*, 2018, p1-11.
- Zhang, J., Diao, B., Xuelin, Xu, J., & Tang, F. (2019). 'TLR2 and TLR4 mediate an activation of adipose tissue renin-angiotensin system induced by uric acid', *Biochimie*, 162, p125-133.
- Zhou, Y., Fang, L., Jiang, L., Wen, P., Cao, H., He, W., *et al.* (2012). 'Uric acid induces renal inflammation via activating tubular NF- $\kappa$ B signaling pathway', *PLoS One*, 7(6).